Insights

  • Date

  • Content Type

  • Reset

Article

Europe’s complex reimbursement process puts access to ATMPs at risk

25.07.22

By By Emma Cheesman-Ungstrup and Alberto Rubio

A potential crisis with advanced therapy medicinal products (ATMPs) is looming in Europe. Concerns over

Article

Run like clockwork | Building successful partnerships with scientific due diligence

1.07.22

By Diane Seimetz & Joerg Schneider

For biotech companies and academic developers wishing to partner with larger firms is perhaps best…

Article

Bridging the perceived regulatory guideline gap for innovative medicines

21.06.22

By Jörg Schneider

There is a perception that regulatory guideline gaps across advanced therapeutic medicinal products (ATMPs) –

Article

PRIME versus ILAP: Selecting the right pathway for gene therapy innovators

21.06.22

By Francesco Lanucara

To all intents and purposes, EMA’s PRIME and MHRA’s Innovative Licensing and Access Pathway (ILAP)

Article

Scientific Due Diligence: The Key to Successful Partnerships

16.06.22

By Diane Seimetz & Jörg Schneider

Planning for partnering, mergers and acquisitions must be done carefully, particularly if you need to

Article

Scientific Due Diligence: The Force Behind Biopharma Merger and Acquisition Success.

16.06.22

By Diane Seimetz & Jörg Schneider

Partnering, mergers and acquisitions (M&As), and product licensing require careful planning, particularly…..